Repro Med Sys Inc (REPR) 0.4500 $REPR
RMS Medical Products Posts First Quarter 2017 Results
ACCESSWIRE - Mon Jun 27, 2:18PM CDT
Double digit growth in revenue and adjusted EBITDA the result of accelerated sales and marketing efforts both domestically and international Hosting first International Distributor Meeting in Europe Continued gross margin expansion as lean initiatives come to fruition Thanks Cyril Narishkin for his service as President, Interim COO and Board Director
Repro Med Systems, Inc. Posts Fourth Quarter and Fiscal Year 2016 Results and Announces New Member of the Board of Directors
PR Newswire - Wed May 18, 4:29PM CDT
Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) today announced its financial results for the fourth quarter and fiscal year ended February 29, 2016.
Repro Med Systems, Inc. Gives Business Update Including Preliminary Revenue Results for Q4 2016
ACCESSWIRE - Thu Mar 31, 8:43AM CDT
CHESTER, NY / ACCESSWIRE / March 31, 2016 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) announced that fourth quarter preliminary net revenues will exceed $3.2 million, representing a slight increase over the $3.1 million of the previous quarter. Sales are led by the Company's proprietary infusion products. The Company's fiscal year ended February 29, 2016.
Markets: Investors Looking Toward Renewed Momentum - Research on SpectraSCIENCE, Blue Sphere, Repro-Med Systems and Inpex
ACCESSWIRE - Fri Mar 11, 7:18AM CST
NEW YORK, NY / ACCESSWIRE / March 11, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: SpectraSCIENCE Inc. (OTC: SCIE), Blue Sphere Corp. (OTC: BLSP), Repro-Med Systems Inc. (OTC: REPR) and Inpex Corp. (OTC: IPXHY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Repro Med Systems, Inc. Responds to FDA Warning Letter
BusinessWire - Wed Mar 09, 10:56AM CST
Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR), a leading developer and manufacturer of medical devices and supplies, announced that on February 26, 2016, RMS Medical Products, Inc. ("RMS"
received a Warning Letter (WL NYK-2016-26) from the New York District Office of US Food and Drug Administration ("FDA" based on the observations of an FDA inspection which occurred in June 2015.
Repro Med Systems Announces Share Buyback
ACCESSWIRE - Wed Sep 30, 1:57PM CDT
CHESTER, NY / ACCESSWIRE / September 30, 2015 / REPRO MED SYSTEMS, INC. (OTCQX: REPR) announced today that its Board of Directors has authorized a stock repurchase program pursuant to which the Company will make open market purchases of up to 1,000,000 shares of the Company's Outstanding Common Stock. The purchases will be made through a broker to be designated by the Company with price, timing and volume restrictions based on average daily trading volume, consistent with the safe harbor rules of the Securities and Exchange Commission for such repurchases.
Repro Med Systems, Inc. Posts Strong Revenue Growth and Productivity Gains
ACCESSWIRE - Wed Sep 30, 12:14PM CDT
CHESTER, NY / ACCESSWIRE / September 30, 2015 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) announced that its second quarter net revenues for fiscal 2016 increased 26.4% over the previous year's Q2, led by the Company's sales of proprietary infusion products. The Company's current fiscal year ends February 28, 2016.
Repro Med Systems, Inc. Qualifies To Trade On OTCQX Market
ACCESSWIRE - Fri Sep 18, 6:31AM CDT
CHESTER, NY / ACCESSWIRE / September 18, 2015 / Repro Med Systems, Inc., dba RMS Medical Products (OTCQX: REPR), a manufacturer of medical devices for the ambulatory (home and institution) infusion market, has qualified to trade on the OTCQX(R) Best Market. Repro Med begins trading today on OTCQX under the symbol "REPR." U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
OTC Markets Group Welcomes Repro Med Systems to OTCQX
PR Newswire - Fri Sep 18, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial markets, today announced Repro Med Systems, Inc. (OTCQX: REPR), a manufacturer of medical devices for the ambulatory infusion market, has qualified to trade on the OTCQX® Best Market.
Repro Med Systems, Inc. (REPR) Announces Appointment of New CFO
ACCESSWIRE - Tue Jan 20, 6:04AM CST
CHESTER, NY / ACCESSWIRE / January 20, 2015 / Repro-Med Systems, Inc. dba RMS Medical Products (OTCQB:REPR) today announced the appointment of Karen Fisher who will serve as Chief Financial Officer of RMS effective January 28th, 2015.
NYT: 12.09 (-0.01)
Repro Med Systems, Inc. (Repr) Announces Strong Results for Third Quarter Ended November 30, 2014
ACCESSWIRE - Tue Dec 23, 11:14AM CST
CHESTER, NY / ACCESSWIRE / December 23, 2014 / Repro Med Systems, Inc. dba RMS Medical Products (OTC stock symbol REPR) today announced that its year-to-date net revenues for fiscal year 2015 are up 28.6% compared with last year, led by its line of home infusion products, while third quarter net revenues for fiscal 2015 increased 21.8% from fiscal 2014. The company's current fiscal year ends February 28, 2015.
RMS Medical Products Posts First Quarter 2017 Results
ACCESSWIRE - Mon Jun 27, 2:18PM CDT
Double digit growth in revenue and adjusted EBITDA the result of accelerated sales and marketing efforts both domestically and international Hosting first International Distributor Meeting in Europe Continued gross margin expansion as lean initiatives come to fruition Thanks Cyril Narishkin for his service as President, Interim COO and Board Director
Repro Med Systems, Inc. Posts Fourth Quarter and Fiscal Year 2016 Results and Announces New Member of the Board of Directors
PR Newswire - Wed May 18, 4:29PM CDT
Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) today announced its financial results for the fourth quarter and fiscal year ended February 29, 2016.
Repro Med Systems, Inc. Gives Business Update Including Preliminary Revenue Results for Q4 2016
ACCESSWIRE - Thu Mar 31, 8:43AM CDT
CHESTER, NY / ACCESSWIRE / March 31, 2016 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) announced that fourth quarter preliminary net revenues will exceed $3.2 million, representing a slight increase over the $3.1 million of the previous quarter. Sales are led by the Company's proprietary infusion products. The Company's fiscal year ended February 29, 2016.
Markets: Investors Looking Toward Renewed Momentum - Research on SpectraSCIENCE, Blue Sphere, Repro-Med Systems and Inpex
ACCESSWIRE - Fri Mar 11, 7:18AM CST
NEW YORK, NY / ACCESSWIRE / March 11, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: SpectraSCIENCE Inc. (OTC: SCIE), Blue Sphere Corp. (OTC: BLSP), Repro-Med Systems Inc. (OTC: REPR) and Inpex Corp. (OTC: IPXHY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Repro Med Systems, Inc. Responds to FDA Warning Letter
BusinessWire - Wed Mar 09, 10:56AM CST
Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR), a leading developer and manufacturer of medical devices and supplies, announced that on February 26, 2016, RMS Medical Products, Inc. ("RMS"
received a Warning Letter (WL NYK-2016-26) from the New York District Office of US Food and Drug Administration ("FDA" based on the observations of an FDA inspection which occurred in June 2015. Repro Med Systems Announces Share Buyback
ACCESSWIRE - Wed Sep 30, 1:57PM CDT
CHESTER, NY / ACCESSWIRE / September 30, 2015 / REPRO MED SYSTEMS, INC. (OTCQX: REPR) announced today that its Board of Directors has authorized a stock repurchase program pursuant to which the Company will make open market purchases of up to 1,000,000 shares of the Company's Outstanding Common Stock. The purchases will be made through a broker to be designated by the Company with price, timing and volume restrictions based on average daily trading volume, consistent with the safe harbor rules of the Securities and Exchange Commission for such repurchases.
Repro Med Systems, Inc. Posts Strong Revenue Growth and Productivity Gains
ACCESSWIRE - Wed Sep 30, 12:14PM CDT
CHESTER, NY / ACCESSWIRE / September 30, 2015 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) announced that its second quarter net revenues for fiscal 2016 increased 26.4% over the previous year's Q2, led by the Company's sales of proprietary infusion products. The Company's current fiscal year ends February 28, 2016.
Repro Med Systems, Inc. Qualifies To Trade On OTCQX Market
ACCESSWIRE - Fri Sep 18, 6:31AM CDT
CHESTER, NY / ACCESSWIRE / September 18, 2015 / Repro Med Systems, Inc., dba RMS Medical Products (OTCQX: REPR), a manufacturer of medical devices for the ambulatory (home and institution) infusion market, has qualified to trade on the OTCQX(R) Best Market. Repro Med begins trading today on OTCQX under the symbol "REPR." U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
OTC Markets Group Welcomes Repro Med Systems to OTCQX
PR Newswire - Fri Sep 18, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial markets, today announced Repro Med Systems, Inc. (OTCQX: REPR), a manufacturer of medical devices for the ambulatory infusion market, has qualified to trade on the OTCQX® Best Market.
Repro Med Systems, Inc. (REPR) Announces Appointment of New CFO
ACCESSWIRE - Tue Jan 20, 6:04AM CST
CHESTER, NY / ACCESSWIRE / January 20, 2015 / Repro-Med Systems, Inc. dba RMS Medical Products (OTCQB:REPR) today announced the appointment of Karen Fisher who will serve as Chief Financial Officer of RMS effective January 28th, 2015.
NYT: 12.09 (-0.01)
Repro Med Systems, Inc. (Repr) Announces Strong Results for Third Quarter Ended November 30, 2014
ACCESSWIRE - Tue Dec 23, 11:14AM CST
CHESTER, NY / ACCESSWIRE / December 23, 2014 / Repro Med Systems, Inc. dba RMS Medical Products (OTC stock symbol REPR) today announced that its year-to-date net revenues for fiscal year 2015 are up 28.6% compared with last year, led by its line of home infusion products, while third quarter net revenues for fiscal 2015 increased 21.8% from fiscal 2014. The company's current fiscal year ends February 28, 2015.
